| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 方盛制药创始于2002年6月，是一家集医药工业、医疗服务、大健康业务于一体的高品质、综合性、科研型医药健康产业集团，旗下拥有多家子公司，2014年12月5日在上海证券交易所成功上市，正式进军资本市场（股票代码：603998）。从建厂到现在，方盛以稳健的发展速度快速崛起，成长为湖南省医药行业的标杆企业，先后获评国家火炬计划重点高新技术企业、中华民族医药百强品牌企业、中国医药行业AAA诚信企业、中国优秀民营企业、国家守合同重信用企业、湖南省省长质量奖企业、湖南省首批示范性医药企业等荣誉称号。 方盛以"您的健康，方盛的追求"为企业使命，成立10多年来，始终在大健康的各领域不断探索、尝试和发展，始终致力于为人类健康服务，构建了以制药工业为主体、以医疗服务和大健康（健康消费、养老）为两翼的“一体两翼”战略布局。制药工业方面，以方盛制药本部为主体，以子公司湘雅制药、海南博大、三花制药等为辅佐合力发展；同时，快速推进方盛利普的国际工厂建设，打造能同时满足FDA和NMPA的国际化技术平台，加快与国际市场接轨；医疗产业方面，以公司参与投资设立的两支产业基金投资标的佰骏医疗和珂信健康为依托，满足人民群众在肾病和肿瘤两大领域不断增长的健康服务需求；健康养老方面，以湘雅制药的“湘雅夕乐苑”为载体，打造“养老院”和“日照中心”相结合的养老生活模式，促进公司在养老产业的发展布局。 方盛以“新药研发能力”为企业核心竞争优势，整合全球顶尖新药研发资源优势，组建高水准研发团队，确立了“中药、化药、生物药”三药并举，以化药复杂制剂的仿制、改良与创新以及走向国际化为重要特色的产品研发战略，不断推进“1+N”模式的国际化大研发体系，实现了多技术、多领域集成式发展。在中药领域，方盛已成功开发"欣雪安"牌心脑血管科、"金蓓贝"牌儿科、"美尔舒"牌妇科、"方盛堂"牌骨伤科等几大品牌系列产品。化药领域，方盛致力于重点开发防治重大疾病的重磅药物，旗下子公司方盛华美自主研发的1类抗癌新药注射用迪安替康钠Ⅰ期临床试验即将完成，美国Lipo研发的注射用紫杉醇（白蛋白结合型）已完成前期研发工作。生物药领域，暨大基因“基因工程药物国家工程研究中心”顺利通过验收，未来发展前景广阔。目前，方盛已实现了对新药研发领域的药学研究、临床研究、一致性评价、生产及销售全价值链的管理。公司现拥有国家认定企业技术中心、博士后科研工作站，承担有国家重大新药创制科技重大专项和多项省部级科技项目，取得药品生产批件160多个，新药证书近20件，发明专利近40项，国际专利2项，丰富的产品储备，为实现方盛战略、满足人民的健康需求提供强大支撑。 方盛组建了一支专业化的营销团队，营销网络覆盖全国各省市各级医院、连锁和单体药店、诊所，凭借过硬的产品质量和专业优质的服务，在医药领域树立了方盛品牌。公司全力推行专业化、学术化营销，通过多样化的学术活动，与各级医疗机构一起，共同助力中国整体医疗水平的提升。 方盛在长沙、海南、辽宁、云南等地拥有多个生产基地，严格按照新版GMP和卓越绩效体系要求组织生产，建立了完善的质量控制和保证体系，执行全过程、全员的质量管理，保障人民的用药质量与安全。其中位于长沙高新区的方盛医药工业园，占地面积150亩，总建筑面积23万平方米，为公司战略发展中需求的产能提供了强大支撑。 未来，方盛将持续以制药工业为主体，强化新药研发核心竞争优势，借助资本的力量撬动产业的发展，最终实现制药工业、医疗服务、健康养老“一体两翼”战略布局，打造高品质、综合性、科研型医药健康产业航母，实现方盛梦，成就健康梦！ | ||||||||||||||||||||||||
| Main Business | 主要从事心脑血管中成药、骨伤科药、儿科药、抗感染药等药品的研发、生产与销售。 | ||||||||||||||||||||||||
| Legal Representative | 周晓莉 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 何仕 | ||||||||||||||||||||||||
| Solicitors | 湖南启元律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0731-88997135 | ||||||||||||||||||||||||
| Fax No | 0731-88908647 | ||||||||||||||||||||||||
| Website | www.fangsheng.com.cn | ||||||||||||||||||||||||
| fs88997135@126.com，603998@fangsheng.com.cn；heshi001@fangsheng.com.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 05/12/2014 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.430 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.290 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 3.316 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.418B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |